Claims

1. A compound of formula (I):



(I)

wherein

- R^1 is H, $(C_1\text{-}C_4)$alkyl, $(C_2\text{-}C_4)$alkenyl, $(C_2\text{-}C_4)$alkynyl or $(CH_2)_m$—R'^1, in which

R'^1 is selected from aromatic heterocycle, phenyl and $(C_3\text{-}C_6)$cycloalkyl wherein the phenyl, the heterocycle and the cycloalkyl groups are unsubstituted or substituted by one to three groups independently selected from

- Q^1, and
- $(C_1\text{-}C_4)$alkyl optionally substituted with one to three groups which are the same or different and which are selected from Q^1,

wherein Q^1 is selected from halogen, NO_2, CN, SO_2CH_3, $SO_2NR^9R^{10}$, OR^9, $COOR^9$, $C(=O)NR^9R^{10}$, NR^9R^{10}, $NR^9SO_2R^{10}$, $NR^9C(=O)R^{10}$ and $C(=O)R^9$ wherein R^9 and R^{10} are the same or different and are selected from H and $(C_1\text{-}C_4)$alkyl;

m is an integer selected from 0, 1 and 2;

$-R^2$ is $(C_1\text{-}C_4)$alkyl, wherein the alkyl group is substituted with one to three substituents independently selected from halogen, OR^9, NR^9R^{10}, $COOR^9$, $C(=O)NR^9R^{10}$, $NHSO_2R^9$ and $C(=O)(C_1\text{-}C_4)$alkyl;

$-R^3$ is $(C_3\text{-}C_6)$cycloalkyl or -A-R'^3, wherein

- A is a bond, $(C_1\text{-}C_3)$alkylene or $(C_2\text{-}C_3)$alkenylene;

- R'^3 is $(C_6$-$C_{12})$aryl or a 5- to 10-membered heterocycle, optionally aromatic, wherein the aryl and the heterocycle groups are unsubstituted or substituted by one to three substituents independently selected from

  - $(C_6$-$C_{12})$aryl,
  - an aromatic heterocyle,
  - Q^2, and
  - $(C_1$-$C_4)$alkyl optionally substituted with one to three groups which are the same or different and which are selected from Q^2,

wherein Q^2 is selected from halogen, NO_2, CN, SO_2CH_3, $SO_2NR^9R^{10}$, OR^9, SR^9, OCH_2CF_3, $COOR^9$, $C(=O)NR^9R^{10}$, NR^9R^{10}, $NR^9SO_2R^{10}$, $NR^9C(=O)R^{10}$ and $C(=O)R^9$;

- R^4 is H or $(C_1$-$C_4)$-alkyl;

- R^5, R^6, R^7 and R^8 are the same or different and are selected from

  - H, Q^3, and
  - $(C_1$-$C_4)$alkyl optionally substituted with one to three groups which are the same or different and which are selected from Q^3,

wherein Q^3 is selected from halogen, NO_2, CN, SO_2CH_3, $SO_2NR^9R^{10}$, OR^9, SR^9 $COOR^9$, $C(=O)NR^9R^{10}$, NR^9R^{10}, $NR^9SO_2R^{10}$, $NR^9C(=O)R^{10}$ and $C(=O)R^9$;

an optical isomer thereof, an N-oxide thereof or a pharmaceutically acceptable salt of the compound, optical isomer or N-oxide;

with the proviso that the following compounds are excluded:

N-(1-benzoyl-6-bromo-1,2,3,4-tetrahydro-2-methyl-4-quinolyl)-acetanilide,

N-(1-benzoyl-6-chloro-1,2,3,4-tetrahydro-2-methyl-4-quinolyl)-acetanilide,

N-(1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-N-(4-methoxyphenyl)-2-methyl-propanamide,

N-[1-(4-fluorobenzoyl)-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenyl-butanamide,

N-phenyl-N-[1,2,3,4-tetrahydro-1-(3-methoxybenzoyl)-2-methyl-4-quinolinyl]-pentanamide,

N-[1-[(4-fluorophenyl)acetyl]-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenyl-propanamide,

N-(1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-2,2-dimethyl-N-phenyl-

propanamide,
N-(1-benzoyl-6-bromo-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-N-phenyl-pentanamide,
N-[1-(2-furanylcarbonyl)-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenyl-acetamide,
2-methyl-N-phenyl-N-[1,2,3,4-tetrahydro-1-(3-methoxybenzoyl)-2-methyl-4-quinolinyl]-propanamide,
2,2,2-trifluoro-N-phenyl-N-[1,2,3,4-tetrahydro-1-(3-methoxybenzoyl)-2-methyl-4-quinolinyl]-acetamide,
N-(1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-N-(3-methoxyphenyl)-acetamide,
N-(1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-N-(4-methylphenyl)-acetamide,
N-[1-(4-chloro-3-nitrobenzoyl)-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenyl-acetamide,
N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-(3-nitrobenzoyl)-4-quinolinyl]-acetamide,
N-phenyl-N-[1,2,3,4-tetrahydro-1-[3-(4-methoxyphenyl)-1-oxo-2-propenyl]-2-methyl-4-quinolinyl]-acetamide,
N-[1-(3-chlorobenzoyl)-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenyl-acetamide,
N-[1-(3-fluorobenzoyl)-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenyl-acetamide,
N-[1-[4-(1,1-dimethylethyl)benzoyl]-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenyl-acetamide,
N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-(1-oxo-3-phenyl-2-propenyl)-4-quinolinyl]-acetamide,
N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-(2-thienylcarbonyl)-4-quinolinyl]-acetamide,
N-phenyl-N-[1,2,3,4-tetrahydro-1-(4-methoxybenzoyl)-2-methyl-4-quinolinyl]-acetamide,
N-[1-(3,5-dinitrobenzoyl)-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenyl-acetamide,

N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-(4-nitrobenzoyl)-4-quinolinyl]-acetamide,

N-phenyl-N-[1,2,3,4-tetrahydro-1-(2-iodobenzoyl)-2-methyl-4-quinolinyl]-acetamide,

N-phenyl-N-[1,2,3,4-tetrahydro-1-(3-methoxybenzoyl)-2-methyl-4-quinolinyl]-acetamide,

N-(1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-N-phenyl-pentanamide,

N-(1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-N-phenyl-butanamide,

N-(1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-N-phenyl-propanamide,

1-benzoyl-1,2,3,4-tetrahydro-4-(N-phenylacetamido)-quinaldine,

N-[(1-benzoyl-1, 2, 3, 4-tetrahydro-2-methyl-4-quinolinyl]-2-methyl-N-phenyl propanamide;

N-[1-(4-bromobenzoyl)-1,2,3,4-tetrahydro-2,6-dimethyl-4-quinolinyl]-acetamide;

N-(1-benzoyl-1,2,3,4-tetrahydro-2,6-dimethyl-4-quinolinyl)-acetamide; and

N-(1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-acetamide.

2. A compound of formula (Ia) or formula (Ib), or a racemic mixture of formula (Ia) and (Ib):



(Ia)



(Ib)

- R^1 is H, $(C_1$-$C_4)$alkyl, $(C_2$-$C_4)$alkenyl, $(C_2$-$C_4)$alkynyl or $(CH_2)_m$—R'^1, in which

R'^1 is selected from aromatic heterocycle, phenyl and $(C_3$-$C_6)$cycloalkyl wherein the phenyl, the heterocycle and the cycloalkyl groups are unsubstituted or substituted by one to three groups independently selected from

- Q^1, and
- $(C_1$-$C_4)$alkyl optionally substituted with one to three groups which are the same or different and which are selected from Q^1,

wherein Q^1 is selected from halogen, NO_2, CN, SO_2CH_3, $SO_2NR^9R^{10}$, OR^9, $COOR^9$, $C(=O)NR^9R^{10}$, NR^9R^{10}, $NR^9SO_2R^{10}$, $NR^9C(=O)R^{10}$ and $C(=O)R^9$ wherein R^9 and R^{10} are the same or different and are selected from H and (C_1-C_4)alkyl;

m is an integer selected from 0, 1 and 2;

$-R^2$ is (C_1-C_4)alkyl, wherein the alkyl group is substituted with one to three substituents independently selected from halogen, OR^9, NR^9R^{10}, $COOR^9$, $C(=O)NR^9R^{10}$, $NHSO_2R^9$ and $C(=O)(C_1-C_4)$alkyl;

$-R^3$ is (C_3-C_6)cycloalkyl or -A-R'^{3}, wherein

- A is a bond, (C_1-C_3)alkylene or (C_2-C_3)alkenylene;
- R'^{3} is (C_6-C_{12})aryl or a 5- to 10-membered heterocycle, optionally aromatic, wherein the aryl and the heterocycle groups are unsubstituted or substituted by one to three substituents independently selected from
  - (C_6-C_{12})aryl,
  - an aromatic heterocyle,
  - Q^2, and
  - (C_1-C_4)alkyl optionally substituted with one to three groups which are the same or different and which are selected from Q^2,

wherein Q^2 is selected from halogen, NO_2, CN, SO_2CH_3, $SO_2NR^9R^{10}$, OR^9, SR^9, OCH_2CF_3, $COOR^9$, $C(=O)NR^9R^{10}$, NR^9R^{10}, $NR^9SO_2R^{10}$, $NR^9C(=O)R^{10}$ and $C(=O)R^9$;

- R^4 is (C_1-C_4)-alkyl;

- R^5, R^6, R^7 and R^8 are the same or different and are selected from
  - H, Q^3, and
  - (C_1-C_4)alkyl optionally substituted with one to three groups which are the same or different and which are selected from Q^3,

wherein Q^3 is selected from halogen, NO_2, CN, SO_2CH_3, $SO_2NR^9R^{10}$, OR^9, SR^9 $COOR^9$, $C(=O)NR^9R^{10}$, NR^9R^{10}, $NR^9SO_2R^{10}$, $NR^9C(=O)R^{10}$ and $C(=O)R^9$;

an N-oxide thereof or a pharmaceutically acceptable salt of the compound or N-oxide;

with the proviso that the following compounds are excluded:

N-[(2R, 4S)-1-benzoyl-1, 2, 3, 4-tetrahydro-2-methyl-4-quinolinyl]-2-methyl-N-phenyl propanamide;

N-[(2R,4S)-1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-2,2-dimethyl-N-phenyl-propanamide;

N-[(2R, 4S)-1-benzoyl-1, 2, 3, 4-tetrahydro-2-methyl-4-quinolinyl]-N-phenyl butanamide;

N-[(2R, 4S)-1-benzoyl-1, 2, 3, 4-tetrahydro-2-methyl-4-quinolinyl]-N-phenyl acetamide;

N-[(2R,4S)-1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenyl-pentanamide; and

N-[(2R,4S)-1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-acetamide.

3. A compound of formula (Ic) or formula (Id), or is a racemic mixture of formula (Ic) and (Id):



(Ic)



(Id)

- R^1 is H, $(C_1\text{-}C_4)$alkyl, $(C_2\text{-}C_4)$alkenyl, $(C_2\text{-}C_4)$alkynyl or $(CH_2)_m$—R'^1, in which

R'^1 is selected from aromatic heterocycle, phenyl and $(C_3\text{-}C_6)$cycloalkyl wherein the phenyl, the heterocycle and the cycloalkyl groups are unsubstituted or substituted by one to three groups independently selected from

- Q^1, and
- $(C_1\text{-}C_4)$alkyl optionally substituted with one to three groups which are the same or different and which are selected from Q^1,

wherein Q^1 is selected from halogen, NO_2, CN, SO_2CH_3, $SO_2NR^9R^{10}$, OR^9, $COOR^9$, $C(=O)NR^9R^{10}$, NR^9R^{10}, $NR^9SO_2R^{10}$, $NR^9C(=O)R^{10}$ and $C(=O)R^9$ wherein R^9 and R^{10} are the same or different and are selected from H and $(C_1\text{-}C_4)$alkyl;

m is an integer selected from 0, 1 and 2;

$-R^2$ is (C_1-C_4)alkyl, wherein the alkyl group is substituted with one to three substituents independently selected from halogen, OR^9, NR^9R^{10}, $COOR^9$, $C(=O)NR^9R^{10}$, $NHSO_2R^9$ and $C(=O)(C_1-C_4)$alkyl;

$-R^3$ is (C_3-C_6)cycloalkyl or -A-R'^{3}, wherein

- A is a bond, (C_1-C_3)alkylene or (C_2-C_3)alkenylene;
- R'^{3} is (C_6-C_{12})aryl or a 5- to 10-membered heterocycle, optionally aromatic, wherein the aryl and the heterocycle groups are unsubstituted or substituted by one to three substituents independently selected from
  - (C_6-C_{12})aryl,
  - an aromatic heterocyle,
  - Q^2, and
  - (C_1-C_4)alkyl optionally substituted with one to three groups which are the same or different and which are selected from Q^2,

wherein Q^2 is selected from halogen, NO_2, CN, SO_2CH_3, $SO_2NR^9R^{10}$, OR^9, SR^9, OCH_2CF_3, $COOR^9$, $C(=O)NR^9R^{10}$, NR^9R^{10}, $NR^9SO_2R^{10}$, $NR^9C(=O)R^{10}$ and $C(=O)R^9$;

- R^4 is (C_1-C_4)-alkyl;

- R^5, R^6, R^7 and R^8 are the same or different and are selected from
  - H, Q^3, and
  - (C_1-C_4)alkyl optionally substituted with one to three groups which are the same or different and which are selected from Q^3,

wherein Q^3 is selected from halogen, NO_2, CN, SO_2CH_3, $SO_2NR^9R^{10}$, OR^9, SR^9 $COOR^9$, $C(=O)NR^9R^{10}$, NR^9R^{10}, $NR^9SO_2R^{10}$, $NR^9C(=O)R^{10}$ and $C(=O)R^9$;

an N-oxide thereof or a pharmaceutically acceptable salt of the compound or N-oxide.

4. A compound according to claim 1 wherein R^1 is H, (C_1-C_4)alkyl, (C_2-C_4)alkenyl, (C_2-C_4)alkynyl or $(CH_2)_m$—R'^{1}, wherein

R'^{1} is selected from phenyl and (C_3-C_6)cycloalkyl wherein the phenyl and the cycloalkyl groups are unsubstituted or substituted by one to three groups selected from

- Q^1, and

- $(C_1\text{-}C_4)$alkyl optionally substituted with one to three groups which are the same or different and which are selected from Q^1,

wherein Q^1 is selected from halogen, NO_2, CN, SO_2CH_3, $SO_2NR^9R^{10}$, OR^9, $COOR^9$, $C(=O)NR^9R^{10}$, NR^9R^{10}, $NR^9SO_2R^{10}$, $NR^9C(=O)R^{10}$ and $C(=O)R^9$.

5. A compound according to claim 2 wherein R^1 is H, $(C_1\text{-}C_4)$alkyl, $(C_2\text{-}C_4)$alkenyl, $(C_2\text{-}C_4)$alkynyl or $(CH_2)_m$—R'^1, wherein

R'^1 is selected from phenyl and $(C_3\text{-}C_6)$cycloalkyl wherein the phenyl and the cycloalkyl groups are unsubstituted or substituted by one to three groups selected from

- Q^1, and
- $(C_1\text{-}C_4)$alkyl optionally substituted with one to three groups which are the same or different and which are selected from Q^1,

wherein Q^1 is selected from halogen, NO_2, CN, SO_2CH_3, $SO_2NR^9R^{10}$, OR^9, $COOR^9$, $C(=O)NR^9R^{10}$, NR^9R^{10}, $NR^9SO_2R^{10}$, $NR^9C(=O)R^{10}$ and $C(=O)R^9$.

6. A compound according to claim 3 wherein R^1 is H, $(C_1\text{-}C_4)$alkyl, $(C_2\text{-}C_4)$alkenyl, $(C_2\text{-}C_4)$alkynyl or $(CH_2)_m$—R'^1, wherein

R'^1 is selected from phenyl and $(C_3\text{-}C_6)$cycloalkyl wherein the phenyl and the cycloalkyl groups are unsubstituted or substituted by one to three groups selected from

- Q^1, and
- $(C_1\text{-}C_4)$alkyl optionally substituted with one to three groups which are the same or different and which are selected from Q^1,

wherein Q^1 is selected from halogen, NO_2, CN, SO_2CH_3, $SO_2NR^9R^{10}$, OR^9, $COOR^9$, $C(=O)NR^9R^{10}$, NR^9R^{10}, $NR^9SO_2R^{10}$, $NR^9C(=O)R^{10}$ and $C(=O)R^9$.

7. A compound according to claim 4 wherein R^1 is $(CH_2)_m$—R'^1, wherein

R'^1 is selected from phenyl and $(C_3\text{-}C_6)$cycloalkyl wherein the phenyl and the cycloalkyl groups are unsubstituted or substituted by 1 to 3 groups selected from OR^9, $COOR^9$and $(C_1\text{-}C_4)$alkyl optionally substituted with $COOR^9$, and

m is an integer selected from 0 and 1.

8. A compound according to claim 5 wherein R^1 is $(CH_2)_m$—R'^1, wherein

R'^1 is selected from phenyl and $(C_3$-$C_6)$cycloalkyl wherein the phenyl and the cycloalkyl groups are unsubstituted or substituted by 1 to 3 groups selected from OR^9, $COOR^9$and $(C_1$-$C_4)$alkyl optionally substituted with $COOR^9$, and

m is an integer selected from 0 and 1.

9. A compound according to claim 6 wherein R^1 is $(CH_2)_m$—R'^1, wherein

R'^1 is selected from phenyl and $(C_3$-$C_6)$cycloalkyl wherein the phenyl and the cycloalkyl groups are unsubstituted or substituted by 1 to 3 groups selected from OR^9, $COOR^9$and $(C_1$-$C_4)$alkyl optionally substituted with $COOR^9$, and

m is an integer selected from 0 and 1.

10. A compound according to claim 1 wherein R^1 is $(C_1$-$C_4)$alkyl, $(C_2$-$C_4)$alkenyl, $(C_2$-$C_4)$alkynyl or $(CH_2)_m$—R'^1, in which

R'^1 is selected from aromatic heterocycle and $(C_3$-$C_6)$cycloalkyl wherein the heterocycle and the cycloalkyl groups are unsubstituted or substituted by one to three groups selected from

- Q^1, and
- $(C_1$-$C_4)$alkyl optionally substituted with one to three groups which are the same or different and which are selected from Q^1,

wherein Q^1 is selected from halogen, NO_2, CN, SO_2CH_3, $SO_2NR^9R^{10}$, OR^9, $COOR^9$, $C(=O)NR^9R^{10}$, NR^9R^{10}, $NR^9SO_2R^{10}$, $NR^9C(=O)R^{10}$ and $C(=O)R^9$.

11. A compound according to claim 2 wherein R^1 is $(C_1$-$C_4)$alkyl, $(C_2$-$C_4)$alkenyl, $(C_2$-$C_4)$alkynyl or $(CH_2)_m$—R'^1, in which

R'^1 is selected from aromatic heterocycle and $(C_3$-$C_6)$cycloalkyl wherein the heterocycle and the cycloalkyl groups are unsubstituted or substituted by one to three groups selected from

- Q^1, and
- $(C_1$-$C_4)$alkyl optionally substituted with one to three groups which are the same or different and which are selected from Q^1,

wherein Q^1 is selected from halogen, NO_2, CN, SO_2CH_3, $SO_2NR^9R^{10}$, OR^9, $COOR^9$, $C(=O)NR^9R^{10}$, NR^9R^{10}, $NR^9SO_2R^{10}$, $NR^9C(=O)R^{10}$ and $C(=O)R^9$.

12. A compound according to claim 3 wherein R^1 is (C_1-C_4)alkyl, (C_2-C_4)alkenyl, (C_2-C_4)alkynyl or $(CH_2)_m$—R'^1, in which

R'^1 is selected from aromatic heterocycle and (C_3-C_6)cycloalkyl wherein the heterocycle and the cycloalkyl groups are unsubstituted or substituted by one to three groups selected from

- Q^1, and
- (C_1-C_4)alkyl optionally substituted with one to three groups which are the same or different and which are selected from Q^1,

wherein Q^1 is selected from halogen, NO_2, CN, SO_2CH_3, $SO_2NR^9R^{10}$, OR^9, $COOR^9$, $C(=O)NR^9R^{10}$, NR^9R^{10}, $NR^9SO_2R^{10}$, $NR^9C(=O)R^{10}$ and $C(=O)R^9$.

13. A compound according to claim10 wherein R^1 is a (C_3-C_6)cycloalkyl wherein the cycloalkyl group is unsubstituted or substituted by one to three groups selected from

- Q^1, and
- (C_1-C_4)alkyl optionally substituted with one to three groups which are the same or different and which are selected from Q^1,

wherein Q^1 is selected from halogen, NO_2, CN, SO_2CH_3, $SO_2NR^9R^{10}$, OR^9, $COOR^9$, $C(=O)NR^9R^{10}$, NR^9R^{10}, $NR^9SO_2R^{10}$, $NR^9C(=O)R^{10}$ and $C(=O)R^9$.

14. A compound according to claim 11 wherein R^1 is a (C_3-C_6)cycloalkyl wherein the cycloalkyl group is unsubstituted or substituted by one to three groups selected from

- Q^1, and
- (C_1-C_4)alkyl optionally substituted with one to three groups which are the same or different and which are selected from Q^1,

wherein Q^1 is selected from halogen, NO_2, CN, SO_2CH_3, $SO_2NR^9R^{10}$, OR^9, $COOR^9$, $C(=O)NR^9R^{10}$, NR^9R^{10}, $NR^9SO_2R^{10}$, $NR^9C(=O)R^{10}$ and $C(=O)R^9$.

15. A compound according to claim 12 wherein R^1 is a (C_3-C_6)cycloalkyl wherein the cycloalkyl group is unsubstituted or substituted by one to three groups selected from

- Q^1, and
- $(C_1$-$C_4)$alkyl optionally substituted with one to three groups which are the same or different and which are selected from Q^1,

wherein Q^1 is selected from halogen, NO_2, CN, SO_2CH_3, $SO_2NR^9R^{10}$, OR^9, $COOR^9$, $C(=O)NR^9R^{10}$, NR^9R^{10}, $NR^9SO_2R^{10}$, $NR^9C(=O)R^{10}$ and $C(=O)R^9$.

16. A compound according to claim 13 wherein R^1 is $(C_3$-$C_6)$cycloalkyl.

17. A compound according to claim 14 wherein R^1 is $(C_3$-$C_6)$cycloalkyl.

18. A compound according to claim 15 wherein R^1 is $(C_3$-$C_6)$cycloalkyl.

19. A compound according to claim 4 wherein R^1 is phenyl unsubstituted or substituted in the para position by a substituent selected from halogen, OR^9, CH_2COOR^9 and CH_2COOR^9.

20. A compound according to claim 5 wherein R^1 is phenyl unsubstituted or substituted in the para position by a substituent selected from halogen, OR^9, CH_2COOR^9 and CH_2COOR^9.

21. A compound according to claim 6 wherein R^1 is phenyl unsubstituted or substituted in the para position by a substituent selected from halogen, OR^9, CH_2COOR^9 and CH_2COOR^9.

22. A compound according to any one of claim 1 to 21 wherein R^2 is $(C_1$-$C_4)$alkyl.

23. A compound according to any one of claim 1 to 21 wherein R^4 is $(C_1$-$C_4)$alkyl.

24. A compound according to claim 22 wherein R^3 is selected from $(C_3$-$C_6)$cycloalkyl and -A-$R^{'3}$, wherein

- A is a bond, $(C_1$-$C_3)$alkylene, straight or branched, or $(C_2$-$C_3)$alkenylene;

- R'^3 is a 5- to 10-membered heterocycle, optionally aromatic, unsubstituted or substituted by 1 to 3 substituents selected from
  - $(C_6$-$C_{12})$aryl, an heterocycle,
  - Q^2, and
  - $(C_1$-$C_4)$alkyl optionally substituted with 1 to 3 groups which are the same or different and which are selected from Q^2,

wherein Q^2 is selected from halogen, NO_2, CN, SO_2CH_3, $SO_2NR^9R^{10}$, OR^9, SR^9, OCH_2CF_3, $COOR^9$, $C(=O)NR^9R^{10}$, NR^9R^{10}, $NR^9SO_2R^{10}$, $NR^9C(=O)R^{10}$ and $C(=O)R^9$, with the proviso that R^3 is not selected from unsubstituted thienyl or unsubstituted furanyl.

25. A compound according to claim 23 wherein R^3 is selected from $(C_3$-$C_6)$cycloalkyl and -A-R'^3, wherein

- A is a bond, $(C_1$-$C_3)$alkylene, straight or branched, or $(C_2$-$C_3)$alkenylene;
- R'^3 is a 5- to 10-membered heterocycle, optionally aromatic, unsubstituted or substituted by 1 to 3 substituents selected from
  - $(C_6$-$C_{12})$aryl,
  - a heterocycle,
  - Q^2, and
  - $(C_1$-$C_4)$alkyl optionally substituted with 1 to 3 groups which are the same or different and which are selected from Q^2,

wherein Q^2 is selected from halogen, NO_2, CN, SO_2CH_3, $SO_2NR^9R^{10}$, OR^9, SR^9, OCH_2CF_3, $COOR^9$, $C(=O)NR^9R^{10}$, NR^9R^{10}, $NR^9SO_2R^{10}$, $NR^9C(=O)R^{10}$ and $C(=O)R^9$, with the proviso that R^3 is not selected from unsubstituted thienyl or unsubstituted furanyl.

26. A compound according to claim 22 wherein R^3 is selected from -A-R'^3, wherein

- A is a bond, straight or branched $(C_1$-$C_3)$alkylene, or $(C_2$-$C_3)$alkenylene;
- R'^3 is a phenyl, unsubstituted or substituted by one to three substituents selected from
  - $(C_6$-$C_{12})$aryl,
  - n heterocycle,
  - Q^2, and

- $(C_1$-$C_4)$alkyl optionally substituted with one to three groups which are the same or different and which are selected from Q^2,

wherein Q^2 is selected from halogen, NO_2, CN, SO_2CH_3, $SO_2NR^9R^{10}$, OR^9, SR^9, OCH_2CF_3, $COOR^9$, $C(=O)NR^9R^{10}$, NR^9R^{10}, $NR^9SO_2R^{10}$, $NR^9C(=O)R^{10}$ and $C(=O)R^9$.

27. A compound according to claim 23 wherein R^3 is selected from -A-R'^3, wherein

- A is a bond, straight or branched $(C_1$-$C_3)$alkylene, or $(C_2$-$C_3)$alkenylene;
- R'^3 is a phenyl, unsubstituted or substituted by one to three substituents selected from
  - $(C_6$-$C_{12})$aryl,
  - n heterocycle,
  - Q^2, and
  - $(C_1$-$C_4)$alkyl optionally substituted with one to three groups which are the same or different and which are selected from Q^2,

wherein Q^2 is selected from halogen, NO_2, CN, SO_2CH_3, $SO_2NR^9R^{10}$, OR^9, SR^9, OCH_2CF_3, $COOR^9$, $C(=O)NR^9R^{10}$, NR^9R^{10}, $NR^9SO_2R^{10}$, $NR^9C(=O)R^{10}$ and $C(=O)R^9$.

28. A compound according to claim 24 wherein R^5, R^6, R^7 and R^8 are the same or different and are selected from H, halogen and OR^9.

29. A compound according to claim 25 wherein R^5, R^6, R^7 and R^8 are the same or different and are selected from H, halogen and OR^9.

30. A compound according to claim 26 wherein R^5, R^6, R^7 and R^8 are the same or different and are selected from H, halogen and OR^9.

31. A compound according to claim 27 wherein R^5, R^6, R^7 and R^8 are the same or different and are selected from H, halogen and OR^9.

32. A compound selected from the group consisting of

Cis-N-[2-Methyl-1-(pyridine-4-carbonyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide;

Cis-N-[2-Methyl-1-(1-oxy-pyridine-4-carbonyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide;
Cis-N-[1-(4-Hydroxy-benzoyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide;
Cis-N-[2-Methyl-1-(4-trifluoromethyl-benzoyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide;
Cis-N-[1-(4-Cyano-benzoyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide;
Cis-N-[1-(4-Chloro-benzoyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide;
4-[Cis-4-(Acetyl-phenyl-amino)-2-methyl-3,4-dihydro-2H-quinoline-1-carbonyl]-benzoic acid methyl ester;
4-[Cis-4-(Acetyl-phenyl-amino)-2-methyl-3,4-dihydro-2H-quinoline-1-carbonyl]-benzoic acid;
Cis-N-[2-Methyl-1-(3-phenyl-propionyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide;
Cis-N-[2-Methyl-1-(5-methyl-thiophene-2-carbonyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide;
Cis-N-[1-(Benzofurazan-5-carbonyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide;
Cis-N-(2-Methyl-1-phenylacetyl-1,2,3,4-tetrahydro-quinolin-4-yl)-N-phenyl-acetamide;
Cis-N-[2-Methyl-1-(pyrazine-2-carbonyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide;
Cis-N-[1-(6-Chloro-pyridine-3-carbonyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide;
Cis-N-[2-Methyl-1-(6-trifluoromethyl-pyridine-3-carbonyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide;
Cis-N-[1-(2,6-Dimethoxy-pyridine-3-carbonyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide;
Cis-N-[1-(2-Methoxy-pyridine-3-carbonyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide;
Cis-N-[2-Methyl-1-(2-methylsulfanyl-pyridine-3-carbonyl)-1,2,3,4-tetrahydro-

quinolin-4-yl]-N-phenyl-acetamide;
Cis-N-[1-(2-Chloro-pyridine-3-carbonyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide;
Cis-N-[2-Methyl-1-(5-methyl-pyrazine-2-carbonyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide;
Cis-N-[1-(2-Chloro-6-methyl-pyridine-3-carbonyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide;
Cis-N-[1-(4-Chloro-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-3-carbonyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide;
Cis-N-[2-Methyl-1-(6-(2,2,2-trifluoro-ethoxy)-pyridine-3-carbonyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide;
Cis-N-[2-Methyl-1-(2-propylsulfanyl-pyridine-3-carbonyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide;
Cis-N-[1-(5,6-Dichloro-pyridine-3-carbonyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide;
Cis-N-[1-(2,6-Dichloro-pyridine-3-carbonyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide;
Cis-N-[2-Methyl-1-(4-methyl-[1,2,3]thiadiazole-5-carbonyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide;
Cis-N-[2-Methyl-1-(5-methyl-isoxazole-3-carbonyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide;
Cis-N-[1-(2,5-Dimethyl-2H-pyrazole-3-carbonyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide;
Cis-N-[2-Methyl-1-(1-methyl-1H-pyrrole-2-carbonyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide;
Cis-N-[1-(Isoxazole-5-carbonyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide;
Cis-N-[2-Methyl-1-(5-methyl-isoxazole-4-carbonyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide;
Cis-N-[1-(2,4-Dimethyl-thiazole-5-carbonyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide;
Cis-N-[1-(5-Chloro-thiophene-2-carbonyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide;

Cis-N-[1-(1,5-Dimethyl-1H-pyrazole-3-carbonyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide;

Cis-N-[2-Methyl-1-(4-methyl-isothiazole-5-carbonyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide

Cis-5-[4-(Acetyl-phenyl-amino)-2-methyl-3,4-dihydro-2H-quinoline-1-carbonyl]-thiophene-2-carboxylic acid dimethylamide

Cis-N-[1-(4-Hydroxy-quinoline-6-carbonyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide

Cis-N-[1-(4-tert-Butyl-thiazole-2-carbonyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide

Cis-N-[1-(2-Ethyl-pyridine-4-carbonyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide

Cis-N-[1-(3,6-Dichloro-pyridine-2-carbonyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide

Cis-N-[1-(4-Chloro-2H-pyrazole-3-carbonyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide

Cis-2-[4-(Acetyl-phenyl-amino)-2-methyl-3,4-dihydro-2H-quinoline-1-carbonyl]-isonicotinic acid methyl ester

Cis-N-[2-Methyl-1-(4-[1,2,4]triazol-4-yl-benzoyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide

Cis-N-[1-(2,6-Dimethoxy-pyridine-4-carbonyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide

Cis-N-[1-(5-Ethyl-isoxazole-3-carbonyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide

Cis-N-[2-Methyl-1-(2-tetrazol-1-yl-pyridine-4-carbonyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide

Cis-N-[2-Methyl-1-(5-propyl-isoxazole-3-carbonyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide

Cis-N-[1-(5-Isobutyl-2-methyl-2H-pyrazole-3-carbonyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide

Cis-N-[1-(5-Bromo-furan-2-carbonyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide

Cis-N-[2-Methyl-1-(6-phenyl-pyridine-3-carbonyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide

Cis-N-[2-Methyl-1-(2-phenyl-pyridine-4-carbonyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide

Cis-N-[2-Methyl-1-(quinoline-6-carbonyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide

Cis-N-[1-(3,4-Dimethoxy-furan-2-carbonyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide

Cis-N-[2-Methyl-1-(3-methyl-furan-2-carbonyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide

Cis-N-[1-(2,5-Dimethyl-furan-3-carbonyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide

Cis-N-[1-(2,4-Dimethyl-oxazole-5-carbonyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide

Cis-N-[1-(5-Methoxymethyl-furan-2-carbonyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide

Cis-N-[1-(5-Fluoro-pyridine-3-carbonyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide

Cis-N-[2-Methyl-1-(quinoline-2-carbonyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide

Cis-N-[2-Methyl-1-(6-methyl-pyridine-3-carbonyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide

Cis-N-[2-Methyl-1-(quinoline-3-carbonyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide

Cis-N-[2-Methyl-1-(1H-pyrazole-3-carbonyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide

Cis-N-[2-Methyl-1-(2H-pyrazole-3-carbonyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide

Cis-N-[1-(5-Isobutyl-isoxazole-3-carbonyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide

Cis-N-[2-Methyl-1-(quinoline-4-carbonyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide

Cis-N-[2-Methyl-1-(6-methyl-pyridine-2-carbonyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide

Cis-N-[2-Methyl-1-(quinoxaline-5-carbonyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide

Cis-N-[1-(3-Methoxy-thiophene-2-carbonyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide

Cis-N-[1-(5-tert-Butyl-2-methyl-furan-3-carbonyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide

Cis-N-[1-(5-Ethyl-2-methyl-2H-pyrazole-3-carbonyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide

Cis-N-[2-Methyl-1-([1,2,5]thiadiazole-3-carbonyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide

Cis-N-[2-Methyl-1-(2-methyl-5-propyl-2H-pyrazole-3-carbonyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide

Cis-N-(1-Benzoyl-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-N-Benzyl-acetamide;

Cis-N-Benzyl-N-[2-methyl-1-(thiophene-2-carbonyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-acetamide;

Trans-N-Benzyl-N-[2-methyl-1-(thiophene-2-carbonyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-acetamide;

Cis-N-Cyclohexyl-N-[2-methyl-1-(thiophene-2-carbonyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-acetamide;

Cis-N-(1-Benzoyl-6-methoxy-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl)-N-phenyl-acetamide;

Cis-N-(1-Benzoyl-6-hydroxy-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl)-N-phenyl-acetamide;

Cis-N-(1-Benzoyl-6-chloro-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl)-N-phenyl-acetamide;

N-(1-Benzoyl-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl)-N-prop-2-ynyl-acetamide;

Cis-N-(1-Benzoyl-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl)-N-(4-methoxy-phenyl)-acetamide;

Cis-N-(1-Benzoyl-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl)-N-(4-hydroxy-

phenyl)-acetamide;
Cis-{4-[Acetyl-(1-benzoyl-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl)-amino]-phenyl}-acetic acid ethyl ester;
Cis-N-(1-Benzoyl-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl)-N-phenyl-malonamic acid methyl ester;
Cis-N-(1-Benzoyl-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl)-N-phenyl-malonamic acid;
Cis-N-[2-Methyl-1-(pyridine-3-carbonyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide;
Cis-N-(1-Benzoyl-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl)-N-Cyclopropyl-acetamide;
Cis-N-Cyclopropyl-N-[2-methyl-1-(pyridine-3-carbonyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-acetamide
(+)-Cis-N-cyclopropyl-N-[2-methyl-1-(pyridine-3-carbonyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-acetamide
(-)-Cis-N-cyclopropyl-N-[2-methyl-1(pyridine-3-carbonyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-acetamide;
Cis-N-Cyclopropyl-N-[2-methyl-1-(3-methyl-isoxazole-5-carbonyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-acetamide;
Cis-N-Phenyl-N-[1-(thiophene-2-carbonyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-acetamide;
Cis-N-(1-Benzoyl-1,2,3,4-tetrahydro-quinolin-4-yl)-N-phenyl-acetamide
Cis-N-[2-Ethyl-1-(pyridine-3-carbonyl)-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide; and
Cis-N-Ethyl-N-[2-Methyl-1-(pyridine-3-carbonyl)-1,2,3,4-tetrahydro-quinolin-yl]-acetamide.

33. A pharmaceutical composition comprising a compound of of formula (I):



(I)

wherein

- R^1 is H, $(C_1\text{-}C_4)$alkyl, $(C_2\text{-}C_4)$alkenyl, $(C_2\text{-}C_4)$alkynyl or $(CH_2)_m$—R'^1, in which

R'^1 is selected from aromatic heterocycle, phenyl and $(C_3\text{-}C_6)$cycloalkyl wherein the phenyl, the heterocycle and the cycloalkyl groups are unsubstituted or substituted by one to three groups independently selected from

- Q^1, and
- $(C_1\text{-}C_4)$alkyl optionally substituted with one to three groups which are the same or different and which are selected from Q^1,

wherein Q^1 is selected from halogen, NO_2, CN, SO_2CH_3, $SO_2NR^9R^{10}$, OR^9, $COOR^9$, $C(=O)NR^9R^{10}$, NR^9R^{10}, $NR^9SO_2R^{10}$, $NR^9C(=O)R^{10}$ and $C(=O)R^9$ wherein R^9 and R^{10} are the same or different and are selected from H and $(C_1\text{-}C_4)$alkyl;

m is an integer selected from 0, 1 and 2;

$-R^2$ is $(C_1\text{-}C_4)$alkyl, wherein the alkyl group is substituted with one to three substituents independently selected from halogen, OR^9, NR^9R^{10}, $COOR^9$, $C(=O)NR^9R^{10}$, $NHSO_2R^9$ and $C(=O)(C_1\text{-}C_4)$alkyl;

$-R^3$ is $(C_3\text{-}C_6)$cycloalkyl or -A-R'^3, wherein

- A is a bond, $(C_1\text{-}C_3)$alkylene or $(C_2\text{-}C_3)$alkenylene;
- R'^3 is $(C_6\text{-}C_{12})$aryl or a 5- to 10-membered heterocycle, optionally aromatic, wherein the aryl and the heterocycle groups are unsubstituted or substituted by one to three substituents independently selected from
  - $(C_6\text{-}C_{12})$aryl,
  - an aromatic heterocyle,
  - Q^2, and

- (C_1-C_4)alkyl optionally substituted with one to three groups which are the same or different and which are selected from Q^2,

wherein Q^2 is selected from halogen, NO_2, CN, SO_2CH_3, $SO_2NR^9R^{10}$, OR^9, SR^9, OCH_2CF_3, $COOR^9$, $C(=O)NR^9R^{10}$, NR^9R^{10}, $NR^9SO_2R^{10}$, $NR^9C(=O)R^{10}$ and $C(=O)R^9$;

- R^4 is H or (C_1-C_4)-alkyl;

- R^5, R^6, R^7 and R^8 are the same or different and are selected from
  - H, Q^3, and
  - (C_1-C_4)alkyl optionally substituted with one to three groups which are the same or different and which are selected from Q^3,

wherein Q^3 is selected from halogen, NO_2, CN, SO_2CH_3, $SO_2NR^9R^{10}$, OR^9, SR^9 $COOR^9$, $C(=O)NR^9R^{10}$, NR^9R^{10}, $NR^9SO_2R^{10}$, $NR^9C(=O)R^{10}$ and $C(=O)R^9$;

an optical isomer thereof, an N-oxide thereof or a pharmaceutically acceptable salt of the compound, optical isomer or N-oxide together with a pharmaceutically acceptable carrier, excipient, diluent or delivery system.

34. A method for treating a disorder in a mammal for which CRTH2 antagonism is relevant comprising administering to said mammal in need of such treatment a compound of of formula (I):



(I)

wherein

- R^1 is H, (C_1-C_4)alkyl, (C_2-C_4)alkenyl, (C_2-C_4)alkynyl or $(CH_2)_m$—R'^1, in which

R'^1 is selected from aromatic heterocycle, phenyl and $(C_3$-$C_6)$cycloalkyl wherein the phenyl, the heterocycle and the cycloalkyl groups are unsubstituted or substituted by one to three groups independently selected from

- Q^1, and
- $(C_1$-$C_4)$alkyl optionally substituted with one to three groups which are the same or different and which are selected from Q^1,

wherein Q^1 is selected from halogen, NO_2, CN, SO_2CH_3, $SO_2NR^9R^{10}$, OR^9, $COOR^9$, $C(=O)NR^9R^{10}$, NR^9R^{10}, $NR^9SO_2R^{10}$, $NR^9C(=O)R^{10}$ and $C(=O)R^9$ wherein R^9 and R^{10} are the same or different and are selected from H and $(C_1$-$C_4)$alkyl;

m is an integer selected from 0, 1 and 2;

$-R^2$ is $(C_1$-$C_4)$alkyl, wherein the alkyl group is substituted with one to three substituents independently selected from halogen, OR^9, NR^9R^{10}, $COOR^9$, $C(=O)NR^9R^{10}$, $NHSO_2R^9$ and $C(=O)(C_1$-$C_4)$alkyl;

$-R^3$ is $(C_3$-$C_6)$cycloalkyl or $-A-R'^3$, wherein

- A is a bond, $(C_1$-$C_3)$alkylene or $(C_2$-$C_3)$alkenylene;
- R'^3 is $(C_6$-$C_{12})$aryl or a 5- to 10-membered heterocycle, optionally aromatic, wherein the aryl and the heterocycle groups are unsubstituted or substituted by one to three substituents independently selected from
  - $(C_6$-$C_{12})$aryl,
  - an aromatic heterocyle,
  - Q^2, and
  - $(C_1$-$C_4)$alkyl optionally substituted with one to three groups which are the same or different and which are selected from Q^2,

wherein Q^2 is selected from halogen, NO_2, CN, SO_2CH_3, $SO_2NR^9R^{10}$, OR^9, SR^9, OCH_2CF_3, $COOR^9$, $C(=O)NR^9R^{10}$, NR^9R^{10}, $NR^9SO_2R^{10}$, $NR^9C(=O)R^{10}$ and $C(=O)R^9$;

- R^4 is H or $(C_1$-$C_4)$-alkyl;

- R^5, R^6, R^7 and R^8 are the same or different and are selected from
  - H, Q^3, and
  - $(C_1$-$C_4)$alkyl optionally substituted with one to three groups which are the same or different and which are selected from Q^3,

wherein Q^3 is selected from halogen, NO_2, CN, SO_2CH_3, $SO_2NR^9R^{10}$, OR^9, SR^9 $COOR^9$, $C(=O)NR^9R^{10}$, NR^9R^{10}, $NR^9SO_2R^{10}$, $NR^9C(=O)R^{10}$ and $C(=O)R^9$;
an optical isomer thereof, an N-oxide thereof or a pharmaceutically acceptable salt of said compound, optical isomer or N-oxide.

35. A method of claim 34 wherein said disorder is selected from rheumatoid arthritis, osteoarthritis, atherosclerosis, Crohn's disease, colitis ulcerosa, inflammatory bowel disease; disorders of the skin, psoriasis, eczema, erythema, pruritis, acne, systemic lupus erythematous, chronic obstructive pulmonary disease, angioedema, stroke, diseases marked by reperfusion injury, graft rejection, autoimmune diseases, allergic diseases, allergic asthma, atopic dermatitis, and allergic rhinitis.

36. A method of claim 35 wherein said disorder is selected from asthma and allergic rhinitis.